CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
BI 207127 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01965431
NCT01965431Phase 1Completed
CompareCT.gov

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxifloxacin as Positive Control

Boehringer Ingelheim·interventional·Posted Oct 18, 2013·Updated Apr 14, 2016

In Brief

A Phase 1 clinical trial evaluating BI 207127, BI 207127 placebo, and 3 other interventions for Healthy. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the effect of multiple doses of BI 207127 combined with faldaprevir on cardiac safety parameters in healthy subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 18, 2013
Enrollment StartOct 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.7 years ago

Interventions

BI 207127drug

Medium dose oral administration

BI 207127 placebodrug

Faldaprevir placebodrug

Faldaprevirdrug

Medium dose oral administration

Moxifloxacin (Avalox®)drug